Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
UNCY Stock Summary
Top 10 Correlated ETFs
UNCY
In the News
Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting
LOS ALTOS, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that two posters related to the Company's lead product candidate, oxylanthanum carbonate (OLC), will be presented at the National Kidney Foundation Spring Clinical Meeting taking place May 14-18, 2024, in Long Beach, California.
Unicycive (UNCY) Up on Positive Hyperphosphatemia Study Update
Unicycive (UNCY) rises after the encouraging progress in the late-stage development of its lead candidate, OLC, for the hyperphosphatemia indication. The NDA submission is expected around mid-2024.
Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023
LOS ALTOS, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY) (the “Company” or “Unicycive”), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in two upcoming investor conferences in December 2023.
The 7 Most Undervalued Penny Stocks to Buy in October 2023
Investing in undervalued penny stocks is always going to be about the same few things. Most investors are attempting to find cheap, short-term plays with reasonable catalysts in their favor.
Why Is Unicycive Therapeutics (UNCY) Down 24% Today?
Unicycive Therapeutics (NASDAQ: UNCY ) stock is falling on Friday after the medical company provided investors with an update from regulators. According to the clinical-stage biotechnology company, the FDA wants further information concerning lanthanum dioxycarbonate (LDC).
Unicycive to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
LOS ALTOS, Calif., June 16, 2023 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, announced today that Company CEO, Shalabh Gupta, MD, has been invited to present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest, on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
Analyzing Penny Stocks After a Market Crash, 3 Tips
Use these tips for analyzing penny stocks after a market crash The post Analyzing Penny Stocks After a Market Crash, 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
How to Identify Promising Penny Stocks: 3 Tips
Use these tips for identifying promising penny stocks The post How to Identify Promising Penny Stocks: 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
How to Future Proof Your Penny Stocks Investing Strategy
Use these tips for future proofing your penny stocks strategy The post How to Future Proof Your Penny Stocks Investing Strategy appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Penny Stocks Investing: The Pros and Cons of Day Trading
What you need to know about day trading penny stocks The post Penny Stocks Investing: The Pros and Cons of Day Trading appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
UNCY Financial details
UNCY Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0.06 | |
Net income per share | -0.16 | -0.3 | -0.91 | -1.2 | |
Operating cash flow per share | -0.08 | -0.17 | -0.49 | -1.04 | |
Free cash flow per share | -0.08 | -0.17 | -0.5 | -1.04 | |
Cash per share | 0 | 0 | 1.42 | 0.03 | |
Book value per share | -0.06 | -0.31 | 1.41 | -0.03 | |
Tangible book value per share | -0.06 | -0.31 | 1.41 | -0.03 | |
Share holders equity per share | -0.06 | -0.31 | 1.41 | -0.03 | |
Interest debt per share | 0.04 | 0.32 | 0.08 | 0.01 | |
Market cap | 72.48M | 42.5M | 24.05M | 8.13M | |
Enterprise value | 72.93M | 45.01M | 7.78M | 7.83M | |
P/E ratio | -31.46 | -16.95 | -2.26 | -0.45 | |
Price to sales ratio | 0 | 0 | 0 | 8.55 | |
POCF ratio | -61.64 | -29.13 | -4.17 | -0.52 | |
PFCF ratio | -61.64 | -29.13 | -4.15 | -0.52 | |
P/B Ratio | -82 | -15.91 | 1.46 | -17.45 | |
PTB ratio | -82 | -15.91 | 1.46 | -17.45 | |
EV to sales | 0 | 0 | 0 | 8.23 | |
Enterprise value over EBITDA | -37.15 | -22.28 | -0.87 | -0.43 | |
EV to operating cash flow | -62.01 | -30.85 | -1.35 | -0.5 | |
EV to free cash flow | -62.01 | -30.85 | -1.34 | -0.5 | |
Earnings yield | -0.03 | -0.06 | -0.44 | -2.22 | |
Free cash flow yield | -0.02 | -0.03 | -0.24 | -1.93 | |
Debt to equity | -0.52 | -0.94 | 0.02 | -0.33 | |
Debt to assets | 24.21 | 12.32 | 0.02 | 0.06 | |
Net debt to EBITDA | -0.23 | -1.24 | 1.81 | 0.02 | |
Current ratio | 0.02 | 0.07 | 8.75 | 0.81 | |
Interest coverage | -14.12 | -8.28 | -14.29 | -3.01K | |
Income quality | 0.54 | 0.64 | 0.58 | 0.87 | |
Dividend Yield | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 6.91 | |
Research and developement to revenue | 0 | 0 | 0 | 13.08 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0.01 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | -2.23 | -0.01 | |
Stock based compensation to revenue | 0 | 0 | 0 | 1.1 | |
Graham number | 0.47 | 1.44 | 5.38 | 0.91 | |
ROIC | 4.93 | 14.25 | -0.56 | 115.76 | |
Return on tangible assets | -121.26 | -12.29 | -0.57 | -6.41 | |
Graham Net | -0.06 | -0.34 | 1.23 | -0.19 | |
Working capital | -884K | -2.67M | 16.31M | -640K | |
Tangible asset value | -884K | -2.67M | 16.48M | -466K | |
Net current asset value | -884K | -2.67M | 16.15M | -640K | |
Invested capital | -0.52 | -0.94 | 0.02 | -0.33 | |
Average receivables | 0 | 0 | 0 | 0 | |
Average payables | 0 | 253K | 463K | 817K | |
Average inventory | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 270.83K | 46.51K | |
Days of inventory on hand | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0.01 | |
Inventory turnover | 0 | 0 | 0 | 0 | |
ROE | 2.61 | 0.94 | -0.64 | 38.76 | |
Capex per share | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.06 | 0 | 0.04 | 0 | 0 | |
Net income per share | -0.37 | -0.35 | -1.65 | -0.25 | -0.13 | |
Operating cash flow per share | -0.24 | -0.4 | -0.26 | -0.36 | -0.14 | |
Free cash flow per share | -0.24 | -0.4 | -0.26 | -0.36 | -0.14 | |
Cash per share | 0.47 | 0.03 | 1.6 | 1.24 | 0.44 | |
Book value per share | 0.31 | -0.03 | 0.69 | 0.45 | 0.11 | |
Tangible book value per share | 0.31 | -0.03 | 0.69 | 0.45 | 0.11 | |
Share holders equity per share | 0.31 | -0.03 | 0.69 | 0.45 | 0.11 | |
Interest debt per share | 0.01 | 0.01 | 0.07 | 0.06 | 0.03 | |
Market cap | 8.89M | 8.13M | 31.99M | 19.5M | 28.06M | |
Enterprise value | 2.07M | 7.88M | 8.65M | 1.62M | 14.59M | |
P/E ratio | -0.4 | -0.38 | -0.32 | -1.27 | -1.59 | |
Price to sales ratio | 9.34 | 0 | 47.39 | 0 | 0 | |
POCF ratio | -2.49 | -1.34 | -8.16 | -3.54 | -6.35 | |
PFCF ratio | -2.49 | -1.34 | -8.16 | -3.54 | -6.35 | |
P/B Ratio | 1.92 | -17.45 | 3.04 | 2.86 | 8.17 | |
PTB ratio | 1.92 | -17.45 | 3.04 | 2.86 | 8.17 | |
EV to sales | 2.18 | 0 | 12.81 | 0 | 0 | |
Enterprise value over EBITDA | -0.38 | -1.49 | -2.09 | -0.4 | -2.46 | |
EV to operating cash flow | -0.58 | -1.29 | -2.21 | -0.29 | -3.3 | |
EV to free cash flow | -0.58 | -1.29 | -2.21 | -0.29 | -3.3 | |
Earnings yield | -0.63 | -0.66 | -0.79 | -0.2 | -0.16 | |
Free cash flow yield | -0.4 | -0.75 | -0.12 | -0.28 | -0.16 | |
Debt to equity | 0.04 | -0.43 | 0.09 | 0.14 | 0.25 | |
Debt to assets | 0.02 | 0.07 | 0.04 | 0.04 | 0.04 | |
Net debt to EBITDA | 1.24 | 0.05 | 5.63 | 4.46 | 2.27 | |
Current ratio | 1.8 | 0.81 | 1.64 | 1.42 | 1.2 | |
Interest coverage | -1.85K | -1.78K | -350.17 | -135.06 | 329.89 | |
Income quality | 0.64 | 1.14 | 0.27 | 1.43 | 1.02 | |
Dividend Yield | 0 | 0 | 0.01 | 0 | 0 | |
Payout ratio | 0 | 0 | -0.01 | 0 | 0 | |
Sales general and administrative to revenue | 1.79 | 0 | 2.74 | 0 | 0 | |
Research and developement to revenue | 5.05 | 0 | 4.49 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | -0.05 | 0 | -0.15 | 0 | |
Stock based compensation to revenue | 0.28 | 0 | 0.21 | 0 | 0 | |
Graham number | 1.6 | 0.5 | 5.06 | 1.59 | 0.57 | |
ROIC | -1.11 | 48.44 | -0.58 | -0.5 | -1.13 | |
Return on tangible assets | -0.55 | -1.89 | -0.92 | -0.17 | -0.23 | |
Graham Net | 0.1 | -0.19 | 0.5 | 0.18 | -0.05 | |
Working capital | 4.44M | -640K | 10.21M | 6.51M | 3.11M | |
Tangible asset value | 4.63M | -466K | 10.52M | 6.83M | 3.43M | |
Net current asset value | 4.41M | -640K | 9.5M | 5.88M | 2.56M | |
Invested capital | 0.04 | -0.43 | 0.09 | 0.14 | 0.25 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 1.46M | 1.53M | 728K | 528K | 718K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 199.44K | 38.07K | 1.22K | 514.62 | 1.13K | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0.07 | 0.17 | 0.08 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -1.2 | 11.44 | -2.39 | -0.56 | -1.28 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
UNCY Frequently Asked Questions
What is Unicycive Therapeutics, Inc. stock symbol ?
Unicycive Therapeutics, Inc. is a US stock , located in Los altos of Ca and trading under the symbol UNCY
What is Unicycive Therapeutics, Inc. stock quote today ?
Unicycive Therapeutics, Inc. stock price is $1.45 today.
Is Unicycive Therapeutics, Inc. stock public?
Yes, Unicycive Therapeutics, Inc. is a publicly traded company.